Adoptive immunotherapy of hormone-refractory, stage D2 prostate cancer using ex vivo activated autologous T cells (autolymphocyte therapy): results from a pilot study.
There is no effective therapy available for stage D2 prostate cancer once patients become refractory to hormonal therapy. In a pilot study, we treated 17 patients with hormone-refractory stage D2 prostate cancer using autolymphocyte therapy, an outpatient form of adoptive immunotherapy in which patients are treated with autologous T cells that have been activated ex vivo. Feasibility and safety were documented. Transient PSA reductions up to 66% were noted, suggesting biological activity. Further studies to test the safety and efficacy of autolymphocyte therapy in the treatment of prostate cancer are warranted.
Ross
S
S
Joint Clinical Immunotherapy Program, Boston University School of Medicine, MA.
Liu
V
V
Abulafia
R
R
Hogan
C
C
Osband
M
M
D000368:Aged; D000369:Aged, 80 and over; D002478:Cells, Cultured; D005240:Feasibility Studies; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010641:Phenotype; D010865:Pilot Projects; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
D017430:Prostate-Specific Antigen